Dendreon Pays $40M Over Claims It Inflated Provenge Demand
The deal resolves claims that Dendreon’s overly optimistic forecasts about Provenge sales artificially inflated the company’s stock price, enabling several current and former executives to cash out big, according to the announcement. The settlement has yet to be formally documented and submitted to the federal court in Washington state.
"We are pleased...
To view the full article, register now.